Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,553 | $1,532 | $1,413 | $1,386 |
| % Growth | 1.4% | 8.5% | 1.9% | – |
| Cost of Goods Sold | $345 | $343 | $302 | $292 |
| Gross Profit | $1,210 | $1,190 | $1,111 | $1,094 |
| % Margin | 77.9% | 77.6% | 78.7% | 78.9% |
| R&D Expenses | $281 | $276 | $255 | $271 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $515 | $502 | $466 | $492 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$11 | -$20 | -$4 | $18 |
| Operating Expenses | $785 | $759 | $716 | $781 |
| Operating Income | $425 | $431 | $395 | $313 |
| % Margin | 27.4% | 28.1% | 27.9% | 22.6% |
| Other Income/Exp. Net | -$77 | -$31 | $39 | $78 |
| Pre-Tax Income | $348 | $400 | $434 | $390 |
| Tax Expense | $56 | $64 | $70 | $45 |
| Net Income | $291 | $330 | $358 | $386 |
| % Margin | 18.7% | 21.5% | 25.3% | 27.8% |
| EPS | 0.5 | 0.57 | 0.61 | 0.65 |
| % Growth | -12.3% | -6.6% | -6.2% | – |
| EPS Diluted | 0.5 | 0.56 | 0.61 | 0.65 |
| Weighted Avg Shares Out | 585 | 587 | 587 | 590 |
| Weighted Avg Shares Out Dil | 586 | 588 | 588 | 591 |
| Supplemental Information | – | – | – | – |
| Interest Income | $39 | $37 | $20 | $44 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $39 | $38 | $37 | $43 |
| EBITDA | $388 | $400 | $471 | $484 |
| % Margin | 25% | 26.1% | 33.3% | 34.9% |